{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:45:59Z","timestamp":1763621159722,"version":"build-2065373602"},"reference-count":444,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323989039"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.pmch.2022.05.001","type":"book-chapter","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T09:03:11Z","timestamp":1654592591000},"page":"1-91","source":"Crossref","is-referenced-by-count":14,"title":["Hearing loss drug discovery and medicinal chemistry: Current status, challenges, and opportunities"],"prefix":"10.1016","member":"78","reference":[{"year":"2003","series-title":"Global burden of hearing loss in the year 2000","author":"Mathers","key":"10.1016\/bs.pmch.2022.05.001_bb0010"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/eurpub\/ckr176","article-title":"Global and regional hearing impairment prevalence: an analysis of 42 studies in 29 countries","volume":"23","author":"Stevens","year":"2013","journal-title":"Eur J Public Health"},{"issue":"9859","key":"10.1016\/bs.pmch.2022.05.001_bb0020","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2471\/BLT.21.285643","article-title":"The world report on hearing","volume":"99","author":"Chadha","year":"2021","journal-title":"Bull World Health Organ"},{"issue":"10111","key":"10.1016\/bs.pmch.2022.05.001_bb0030","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(17)31073-5","article-title":"Global hearing health care: new findings and perspectives","volume":"390","author":"Wilson","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000275062","article-title":"Current trends in treating hearing loss in elderly people: a review of the technology and treatment options\u2014a mini-review","volume":"56","author":"Sprinzl","year":"2010","journal-title":"Gerontology"},{"issue":"18","key":"10.1016\/bs.pmch.2022.05.001_bb0040","doi-asserted-by":"crossref","first-page":"R878","DOI":"10.1016\/j.cub.2014.06.053","article-title":"Cochlear implants","volume":"24","author":"Macherey","year":"2014","journal-title":"Curr Biol"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb0045","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1109\/TBME.2017.2718939","article-title":"Challenges in improving Cochlear implant performance and accessibility","volume":"64","author":"Zeng","year":"2017","journal-title":"IEEE Trans Biomed Eng"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tins.2018.01.008","article-title":"Why do hearing aids fail to restore Normal auditory perception?","volume":"41","author":"Lesica","year":"2018","journal-title":"Trends Neurosci"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0055","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3109\/14992027.2013.769066","article-title":"Why do people fitted with hearing aids not wear them?","volume":"52","author":"McCormack","year":"2013","journal-title":"Int J Audiol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.heares.2018.06.008","article-title":"Comorbidities of hearing loss and the implications of multimorbidity for audiological care","volume":"369","author":"Besser","year":"2018","journal-title":"Hear Res"},{"issue":"15","key":"10.1016\/bs.pmch.2022.05.001_bb0065","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/09638280210129162","article-title":"Communication and psychosocial consequences of sensory loss in older adults: overview and rehabilitation directions","volume":"24","author":"Heine","year":"2002","journal-title":"Disabil Rehabil"},{"issue":"Suppl 2","key":"10.1016\/bs.pmch.2022.05.001_bb0070","article-title":"Negative consequences of uncorrected hearing loss\u2014a review","volume":"42","author":"Arlinger","year":"2003","journal-title":"Int J Audiol"},{"issue":"10113","key":"10.1016\/bs.pmch.2022.05.001_bb0075","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","article-title":"Dementia prevention, intervention, and care","volume":"390","author":"Livingston","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0080","article-title":"Speech-in-noise hearing impairment is associated with an increased risk of incident dementia in 82,039 UK biobank participants","author":"Stevenson","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"9904","key":"10.1016\/bs.pmch.2022.05.001_bb0085","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(13)60142-7","article-title":"Tinnitus","volume":"382","author":"Baguley","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0090","series-title":"Handbook of clinical neurology. 129","first-page":"409","article-title":"Chapter 23 - tinnitus","author":"Levine","year":"2015"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.heares.2006.07.007","article-title":"Course of hearing loss and occurrence of tinnitus","volume":"221","author":"Konig","year":"2006","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.heares.2013.12.004","article-title":"Tinnitus in men, mice (as well as other rodents), and machines","volume":"311","author":"Schaette","year":"2014","journal-title":"Hear Res"},{"issue":"38","key":"10.1016\/bs.pmch.2022.05.001_bb0105","doi-asserted-by":"crossref","first-page":"13452","DOI":"10.1523\/JNEUROSCI.2156-11.2011","article-title":"Tinnitus with a normal audiogram: physiological evidence for hidden hearing loss and computational model","volume":"31","author":"Schaette","year":"2011","journal-title":"J Neurosci"},{"issue":"12","key":"10.1016\/bs.pmch.2022.05.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041290","article-title":"Natural history of tinnitus in adults: a cross-sectional and longitudinal analysis","volume":"10","author":"Dawes","year":"2020","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb0115","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamaoto.2021.1049","article-title":"Cross-sectional and longitudinal associations between tinnitus and mental health in a population-based sample of middle-aged and elderly persons","volume":"147","author":"Oosterloo","year":"2021","journal-title":"JAMA Otolaryngol - Head Neck Surg"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/bs.pbr.2021.01.023","article-title":"Tinnitus and its associations with general health, mental health and hearing loss","volume":"262","author":"Stegeman","year":"2021","journal-title":"Prog Brain Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0125","article-title":"Steroids for idiopathic sudden sensorineural hearing loss","volume":"7","author":"Wei","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/lary.24834","article-title":"Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials","volume":"125","author":"Crane","year":"2015","journal-title":"Laryngoscope"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011795","article-title":"Interventions for tinnitus in adults: an overview of systematic reviews","volume":"7","author":"Maldonado Fern\u00e1ndez","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb0140","article-title":"Intratympanic steroids for Meniere's disease or syndrome","author":"Phillips","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0145","first-page":"1","article-title":"Ears Wide Open","author":"Li","year":"2017","journal-title":"BioCentury"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0150","article-title":"The global hearing therapeutic pipeline: 2021","author":"Isherwood","year":"2021","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0155","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/MAO.0000000000002194","article-title":"Hearing protection, restoration, and regeneration: an overview of emerging therapeutics for inner ear and central hearing disorders","volume":"40","author":"Schilder","year":"2019","journal-title":"Otol Neurotol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0160","doi-asserted-by":"crossref","first-page":"107981","DOI":"10.1016\/j.heares.2020.107981","article-title":"Gene therapy for hair cell regeneration: review and new data","author":"Shibata","year":"2020","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2020.107927","article-title":"Viral vectors for gene delivery to the inner ear","volume":"394","author":"Maguire","year":"2020","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2020.107934","article-title":"Practical aspects of inner ear gene delivery for research and clinical applications","volume":"394","author":"Lee","year":"2020","journal-title":"Hear Res"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41434-020-0155-7","article-title":"Recent development of AAV-based gene therapies for inner ear disorders","volume":"27","author":"Lan","year":"2020","journal-title":"Gene Ther"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb0180","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3390\/jcm9072309","article-title":"Inner ear gene therapies take off: current promises and future challenges","volume":"9","author":"Delmaghani","year":"2020","journal-title":"J Clin Med"},{"issue":"Suppl 5(S5)","key":"10.1016\/bs.pmch.2022.05.001_bb0185","first-page":"S1","article-title":"Optimizing atoh1-induced vestibular hair cell regeneration","volume":"124","author":"Staecker","year":"2014","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0190","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10162-017-0634-8","article-title":"Emerging gene therapies for genetic hearing loss","volume":"18","author":"Ahmed","year":"2017","journal-title":"J Assoc Res Otolaryngol"},{"issue":"183","key":"10.1016\/bs.pmch.2022.05.001_bb0195","article-title":"A review of gene, drug and cell-based therapies for usher syndrome","volume":"14","author":"French","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb0200","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033191","article-title":"Cochlear gene therapy","volume":"9","author":"Lustig","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb2226","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nic.2018.09.008","article-title":"Common otologic surgical procedures: clinical decision-making pearls and the role of imaging","volume":"29","author":"Peng","year":"2019","journal-title":"Neuroimaging Clin N Am"},{"issue":"482","key":"10.1016\/bs.pmch.2022.05.001_bb0205","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao0935","article-title":"Delivery of therapeutics to the inner ear: the challenge of the blood-labyrinth barrier","volume":"11","author":"Nyberg","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.410110102","article-title":"Cerebrospinal fluid: a selective review","volume":"11","author":"Cutler","year":"1982","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb0215","doi-asserted-by":"crossref","first-page":"175","DOI":"10.33549\/physiolres.933684","article-title":"Endolymph composition: paradigm or inevitability?","volume":"67","author":"Gagov","year":"2018","journal-title":"Physiol Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0220","series-title":"Handbook of clinical neurophysiology","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-7020-5310-8.00001-6","article-title":"Chapter 1 - anatomy and physiology of the external, middle and inner ear","volume":"vol. 10","author":"Hayes","year":"2013"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0225","first-page":"112","article-title":"Cochlear physiology. II. Mostly electrophysiology","author":"Salvi","year":"2007","journal-title":"The AuDiTory SySTem: AnATomy, PhySioLogy, AnD CLiniCAL CorreLATeS"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb2227","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0361-9230(03)00047-9","article-title":"Structure and innervation of the cochlea","volume":"60","author":"Raphael","year":"2003","journal-title":"Brain Res Bull"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0230","series-title":"Handbook of clinical neurophysiology","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/B978-0-7020-5310-8.00002-8","article-title":"Chapter 2 - anatomy and physiology of auditory pathways and cortex","volume":"vol. 10","author":"Brugge","year":"2013"},{"issue":"9\u201310","key":"10.1016\/bs.pmch.2022.05.001_bb0235","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020","article-title":"Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival","volume":"17","author":"Morgan","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.heares.2018.06.018","article-title":"Local drug delivery to the inner ear: principles, practice, and future challenges","volume":"368","author":"Plontke","year":"2018","journal-title":"Hear Res"},{"issue":"418","key":"10.1016\/bs.pmch.2022.05.001_bb0245","article-title":"Local delivery of therapeutics to the inner ear: the state of the science","volume":"13","author":"Anderson","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejps.2018.05.020","article-title":"Inner ear drug delivery: recent advances, challenges, and perspective","volume":"126","author":"Hao","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"300","key":"10.1016\/bs.pmch.2022.05.001_bb0255","article-title":"Local drug delivery for prevention of hearing loss","volume":"13","author":"Rybak","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"238","key":"10.1016\/bs.pmch.2022.05.001_bb0260","article-title":"Local drug delivery for the treatment of neurotology disorders","volume":"13","author":"Piu","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.heares.2018.05.005","article-title":"Diseases and targets for local drug delivery to the inner ear","volume":"368","author":"Lustig","year":"2018","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0270","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.heares.2018.06.017","article-title":"Anatomical basis of drug delivery to the inner ear","volume":"368","author":"Glueckert","year":"2018","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0275","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.heares.2018.03.002","article-title":"Pharmacokinetic principles in the inner ear: influence of drug properties on intratympanic applications","volume":"368","author":"Salt","year":"2018","journal-title":"Hear Res"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4155\/tde.12.130","article-title":"Drug delivery to the ear","volume":"4","author":"Hoskison","year":"2013","journal-title":"Ther Deliv"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0285","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijpharm.2015.08.015","article-title":"Recent advances in local drug delivery to the inner ear","volume":"494","author":"El Kechai","year":"2015","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb0290","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0378-5955(88)90111-6","article-title":"Volume flow rate of perilymph in the guinea-pig cochlea","volume":"35","author":"Ohyama","year":"1988","journal-title":"Hear Res"},{"issue":"19","key":"10.1016\/bs.pmch.2022.05.001_bb0295","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1359-6446(05)03574-9","article-title":"Local inner-ear drug delivery and pharmacokinetics","volume":"10","author":"Salt","year":"2005","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb0300","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1021\/jm501535r","article-title":"CNS drug design: balancing physicochemical properties for optimal brain exposure","volume":"58","author":"Rankovic","year":"2015","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/bs.pmch.2022.05.001_bb0305","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1021\/acs.jmedchem.6b01469","article-title":"CNS physicochemical property space shaped by a diverse set of molecules with experimentally determined exposure in the mouse brain","volume":"60","author":"Rankovic","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2020.07.006","article-title":"Emerging trends in inhaled drug delivery","volume":"157","author":"Hickey","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0315","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archotol.1951.03750070060005","article-title":"Transtympanic injection of anesthetics for the treatment of M\u00e9ni\u00e9re's syndrome","volume":"54","author":"Ersner","year":"1951","journal-title":"AMA Arch Otolaryngol"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb0320","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/MAO.0b013e31815aee21","article-title":"Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph","volume":"28","author":"Bird","year":"2007","journal-title":"Otol Neurotol"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb0325","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/MAO.0b013e3182255933","article-title":"Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph","volume":"32","author":"Bird","year":"2011","journal-title":"Otol Neurotol"},{"issue":"268","key":"10.1016\/bs.pmch.2022.05.001_bb0330","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fncel.2017.00268","article-title":"Magnetic nanoparticle mediated steroid delivery mitigates cisplatin induced hearing loss","volume":"11","author":"Ramaswamy","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0335","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejps.2018.06.011","article-title":"Toxicology study for magnetic injection of prednisolone into the rat cochlea","volume":"126","author":"Shimoji","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0340","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/10717544.2021.1943059","article-title":"Drug distribution along the cochlea is strongly enhanced by low-frequency round window micro vibrations","volume":"28","author":"Flaherty","year":"2021","journal-title":"Drug Deliv"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb0345","doi-asserted-by":"crossref","first-page":"100945","DOI":"10.1016\/j.isci.2020.100945","article-title":"Local drug delivery to the entire cochlea without breaching its boundaries","volume":"23","author":"Lukashkin","year":"2020","journal-title":"iScience"},{"issue":"161","key":"10.1016\/bs.pmch.2022.05.001_bb0350","article-title":"Drug diffusion along an intact mammalian cochlea","volume":"13","author":"Sadreev","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0355","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.heares.2018.03.006","article-title":"Controlled drug release to the inner ear: concepts, materials, mechanisms, and performance","volume":"368","author":"M\u00e4der","year":"2018","journal-title":"Hear Res"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0360","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00106-016-0285-9","article-title":"Intracochlear drug delivery in combination with cochlear implants","volume":"65","author":"Plontke","year":"2017","journal-title":"HNO"},{"issue":"25","key":"10.1016\/bs.pmch.2022.05.001_bb0365","first-page":"433","article-title":"The differential diagnosis of hearing loss","volume":"108","author":"Zahnert","year":"2011","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb0370","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/gim.2014.2","article-title":"American College of Medical Genetics and Genomics guideline for the clinical evaluation and etiologic diagnosis of hearing loss","volume":"16","author":"Alford","year":"2014","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb0375","first-page":"117","article-title":"Non-syndromic hearing loss: clinical and diagnostic challenges","volume":"32","author":"Vona","year":"2020","journal-title":"Med Genet"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0380","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.mcp.2015.03.008","article-title":"Non-syndromic hearing loss gene identification: A brief history and glimpse into the future","volume":"29","author":"Vona","year":"2015","journal-title":"Mol Cell Probes"},{"issue":"R2","key":"10.1016\/bs.pmch.2022.05.001_bb0385","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1093\/hmg\/ddy158","article-title":"Genetic landscape of auditory dysfunction","volume":"27","author":"Bowl","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb0390","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033217","article-title":"Age-related hearing loss","volume":"9","author":"Bowl","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"20","key":"10.1016\/bs.pmch.2022.05.001_bb0395","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMra050700","article-title":"Newborn hearing screening--a silent revolution","volume":"354","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"issue":"7312","key":"10.1016\/bs.pmch.2022.05.001_bb0400","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/bmj.323.7312.536","article-title":"Prevalence of permanent childhood hearing impairment in the United Kingdom and implications for universal neonatal hearing screening: questionnaire based ascertainment study","volume":"323","author":"Fortnum","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0405","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/14992027.2012.673237","article-title":"The longitudinal follow up of a universal neonatal hearing screen: the implications for confirming deafness in childhood","volume":"51","author":"Watkin","year":"2012","journal-title":"Int J Audiol"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0410","doi-asserted-by":"crossref","first-page":"16094","DOI":"10.1038\/nrdp.2016.94","article-title":"Congenital hearing loss","volume":"3","author":"Korver","year":"2017","journal-title":"Nat Rev Dis Primers"},{"year":"2013","series-title":"Hereditary hearing loss and its syndromes","author":"Toriello","key":"10.1016\/bs.pmch.2022.05.001_bb0415"},{"year":"2021","series-title":"Conductive hearing loss. StatPearls. Treasure Island (FL)","author":"Sooriyamoorthy","key":"10.1016\/bs.pmch.2022.05.001_bb0420"},{"issue":"25","key":"10.1016\/bs.pmch.2022.05.001_bb0425","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMra1616601","article-title":"Hearing loss in adults","volume":"377","author":"Cunningham","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/bs.pmch.2022.05.001_bb0430","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1093\/geront\/gnw033","article-title":"Aging and hearing health: the life-course approach","volume":"56","author":"Davis","year":"2016","journal-title":"Gerontologist"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb0435","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/jnr.24439","article-title":"Pathology and mechanisms of cochlear aging","volume":"98","author":"Keithley","year":"2020","journal-title":"J Neurosci Res"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb0440","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/jnr.24677","article-title":"Age-related hearing loss: A new focus on an age-old puzzle","volume":"98","author":"Nolan","year":"2020","journal-title":"J Neurosci Res"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb0445","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1620\/tjem.219.177","article-title":"Cisplatin ototoxicity and protection: clinical and experimental studies","volume":"219","author":"Rybak","year":"2009","journal-title":"Tohoku J Exp Med"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb0450","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.heares.2006.09.015","article-title":"Mechanisms of cisplatin-induced ototoxicity and prevention","volume":"226","author":"Rybak","year":"2007","journal-title":"Hear Res"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb0455","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/ar.22578","article-title":"Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention","volume":"295","author":"Schacht","year":"2012","journal-title":"Anat Rec"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb0460","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033548","article-title":"Aminoglycoside- and cisplatin-induced ototoxicity: mechanisms and otoprotective strategies","volume":"9","author":"Kros","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0465","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MOO.0b013e3282ef772d","article-title":"Aminoglycoside ototoxicity","volume":"15","author":"Rizzi","year":"2007","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"year":"2009","series-title":"Ototoxicity","key":"10.1016\/bs.pmch.2022.05.001_bb0470"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb0475","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S2352-4642(21)00020-1","article-title":"Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional north American cohort study","volume":"5","author":"Moke","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb0480","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/MPH.0b013e318059c220","article-title":"Ototoxicity from cisplatin therapy in childhood cancer","volume":"29","author":"Coradini","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"34","key":"10.1016\/bs.pmch.2022.05.001_bb0485","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development","volume":"23","author":"Knight","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/bs.pmch.2022.05.001_bb0490","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1200\/JCO.2011.39.1110","article-title":"Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale","volume":"30","author":"Brock","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0495","article-title":"Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection","volume":"2011","author":"Huth","year":"2011","journal-title":"Int J Otolaryngol"},{"issue":"999","key":"10.1016\/bs.pmch.2022.05.001_bb0500","article-title":"Current strategies to combat cisplatin-induced ototoxicity","volume":"11","author":"Yu","year":"2020","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb0505","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1055\/s-0039-1684048","article-title":"Mechanisms of cisplatin-induced ototoxicity and prevention","volume":"40","author":"Rybak","year":"2019","journal-title":"Semin Hear"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0510","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41467-017-01837-1","article-title":"Cisplatin is retained in the cochlea indefinitely following chemotherapy","volume":"8","author":"Breglio","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb0515","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10162-020-00759-y","article-title":"Ototoxicity and platinum uptake following cyclic Administration of Platinum-Based Chemotherapeutic Agents","volume":"21","author":"Gersten","year":"2020","journal-title":"J Assoc Res Otolaryngol"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0520","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000013861","article-title":"Aminoglycoside antibiotics","volume":"5","author":"Forge","year":"2000","journal-title":"Audiol Neurootol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0525","doi-asserted-by":"crossref","first-page":"927","DOI":"10.12688\/f1000research.11310.1","article-title":"Noise-induced and age-related hearing loss: new perspectives and potential therapies","volume":"6","author":"Liberman","year":"2017","journal-title":"F1000Res"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb0530","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.3390\/ijerph18084236","article-title":"Loud music and leisure noise is a common cause of chronic hearing loss, tinnitus and hyperacusis","volume":"18","author":"Pienkowski","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0535","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1121\/1.5132949","article-title":"Prevalence of loud leisure noise activities among a representative sample of Canadians aged 6-79 years","volume":"146","author":"Feder","year":"2019","journal-title":"J Acoust Soc Am"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0540","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40463-017-0219-x","article-title":"Current insights in noise-induced hearing loss: a literature review of the underlying mechanism, pathophysiology, asymmetry, and management options","volume":"46","author":"Le","year":"2017","journal-title":"J Otolaryngol - Head Neck Surg"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0545","doi-asserted-by":"crossref","first-page":"4784385","DOI":"10.1155\/2021\/4784385","article-title":"Noise-induced hearing loss: updates on molecular targets and potential interventions","volume":"2021","author":"Mao","year":"2021","journal-title":"Neural Plast"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0550","doi-asserted-by":"crossref","first-page":"191","DOI":"10.15252\/emmm.201505523","article-title":"Wbp2 is required for normal glutamatergic synapses in the cochlea and is crucial for hearing","volume":"8","author":"Buniello","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb0555","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.heares.2006.10.006","article-title":"Mechanisms of noise-induced hearing loss indicate multiple methods of prevention","volume":"226","author":"Le Prell","year":"2007","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0560","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.heares.2016.12.008","article-title":"Noise-induced cochlear synaptopathy: past findings and future studies","volume":"349","author":"Kobel","year":"2017","journal-title":"Hear Res"},{"issue":"17","key":"10.1016\/bs.pmch.2022.05.001_bb0565","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.281.17.1658","article-title":"Effects of noise on hearing","volume":"281","author":"Clark","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2981-8_1","article-title":"Noise-induced hearing loss: permanent versus temporary threshold shifts and the effects of hair cell versus neuronal degeneration","volume":"875","author":"Liberman","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb0575","article-title":"Interventions to prevent occupational noise-induced hearing loss","volume":"7","author":"Tikka","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255356","article-title":"Workplace noise exposure and the prevalence and 10-year incidence of age-related hearing loss","volume":"16","author":"Gopinath","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0585","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.heares.2016.10.006","article-title":"Long-term noise exposures: A brief review","volume":"349","author":"Davis","year":"2017","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0590","series-title":"Springer handbook of auditory research","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-319-40848-4_5","article-title":"Development of drugs for noise-induced hearing loss","volume":"vol 58","author":"Lynch","year":"2016"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0595","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12881-017-0515-3","article-title":"Effect of GRM7 polymorphisms on the development of noise-induced hearing loss in Chinese Han workers: a nested case-control study","volume":"19","author":"Yu","year":"2018","journal-title":"BMC Med Genet"},{"issue":"14","key":"10.1016\/bs.pmch.2022.05.001_bb0600","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/archinte.168.14.1522","article-title":"Prevalence of hearing loss and differences by demographic characteristics among US adults: data from the National Health and nutrition examination survey, 1999-2004","volume":"168","author":"Agrawal","year":"2008","journal-title":"Arch Intern Med"},{"issue":"1 Pt 2","key":"10.1016\/bs.pmch.2022.05.001_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/00034894931020S101","article-title":"Cochlear pathology in presbycusis","volume":"102","author":"Schuknecht","year":"1993","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0610","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/01.moo.0000134450.99615.22","article-title":"Age-related hearing loss: the status of Schuknecht's typology","volume":"12","author":"Ohlemiller","year":"2004","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb0615","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/jnr.24426","article-title":"Advances in understanding of presbycusis","volume":"98","author":"Tawfik","year":"2020","journal-title":"J Neurosci Res"},{"issue":"45","key":"10.1016\/bs.pmch.2022.05.001_bb0620","doi-asserted-by":"crossref","first-page":"14077","DOI":"10.1523\/JNEUROSCI.2845-09.2009","article-title":"Adding insult to injury: cochlear nerve degeneration after \u201ctemporary\u201d noise-induced hearing loss","volume":"29","author":"Kujawa","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0625","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.heares.2017.01.003","article-title":"Cochlear synaptopathy in acquired sensorineural hearing loss: manifestations and mechanisms","volume":"349","author":"Liberman","year":"2017","journal-title":"Hear Res"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb0630","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/brainsci10100756","article-title":"Perspectives on human hearing loss, Cochlear regeneration, and the potential for hearing restoration therapies","volume":"10","author":"White","year":"2020","journal-title":"Brain Sci"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb0635","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jnr.24556","article-title":"Ultrastructural defects in stereocilia and tectorial membrane in aging mouse and human cochleae","volume":"98","author":"Bullen","year":"2020","journal-title":"J Neurosci Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0640","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.heares.2019.02.015","article-title":"The aging cochlea: towards unraveling the functional contributions of strial dysfunction and synaptopathy","volume":"376","author":"Heeringa","year":"2019","journal-title":"Hear Res"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb0645","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.tins.2020.07.005","article-title":"The effects of age-related hearing loss on the brain and cognitive function","volume":"43","author":"Slade","year":"2020","journal-title":"Trends Neurosci"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0650","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fnmol.2017.00236","article-title":"Recent advancements in the regeneration of auditory hair cells and hearing restoration","volume":"10","author":"Mittal","year":"2017","journal-title":"Front Mol Neurosci"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb0655","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcyt.2017.04.008","article-title":"Regenerative medicine in hearing recovery","volume":"19","author":"Simoni","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0660","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pharmthera.2019.05.003","article-title":"New molecular therapies for the treatment of hearing loss","volume":"200","author":"Ma","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb0665","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1152\/physrev.00053.2017","article-title":"Toward Cochlear therapies","volume":"98","author":"Wang","year":"2018","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb0670","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14728214.2018.1555240","article-title":"An update: emerging drugs for tinnitus","volume":"23","author":"Cederroth","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0675","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-010818-021556","article-title":"Therapeutic approaches to the treatment of tinnitus","volume":"59","author":"Langguth","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0680","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00405-016-4401-y","article-title":"A multidisciplinary systematic review of the treatment for chronic idiopathic tinnitus","volume":"274","author":"Zenner","year":"2017","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb0685","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MAO.0000000000002116","article-title":"Objective measures of tinnitus: a systematic review","volume":"40","author":"Jackson","year":"2019","journal-title":"Otol Neurotol"},{"issue":"802","key":"10.1016\/bs.pmch.2022.05.001_bb0690","article-title":"Why is there no cure for tinnitus?","volume":"13","author":"McFerran","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0695","article-title":"The COMiT'ID study: developing Core outcome domains sets for clinical trials of sound-, psychology-, and pharmacology-based interventions for chronic subjective tinnitus in adults","volume":"22","author":"Hall","year":"2018","journal-title":"Trends Hear"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0700","article-title":"Designing clinical trials for assessing the effectiveness of interventions for tinnitus","volume":"21","author":"Hall","year":"2017","journal-title":"Trends Hear"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0705","article-title":"One size does not fit all: developing common standards for outcomes in early-phase clinical trials of sound-, psychology-, and pharmacology-based interventions for chronic subjective tinnitus in adults","volume":"23","author":"Hall","year":"2019","journal-title":"Trends Hear"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0710","series-title":"International encyclopedia of public health","first-page":"512","article-title":"Hearing disorders","author":"Burkard","year":"2017"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0715","series-title":"Environmental Noise Pollution","first-page":"9","article-title":"Chapter 2 - principles of environmental noise","author":"Murphy","year":"2014"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0720","first-page":"20","article-title":"Hearing ranges of laboratory animals","volume":"46","author":"Heffner","year":"2007","journal-title":"J Am Assoc Lab Anim Sci"},{"author":"LOUISIANA_STATE_UNIVERSITY","key":"10.1016\/bs.pmch.2022.05.001_bb0725"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0730","series-title":"CURRENT Diagnosis & Treatment in otolaryngology\u2014head and neck surgery","article-title":"Audiologic testing","author":"Sweetow","year":"2012"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0735","series-title":"Neurology and clinical neuroscience","first-page":"318","article-title":"Chapter 25 - examination of hearing and balance","author":"Kung","year":"2007"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0740","series-title":"Assessment of peripheral and central auditory function. Head and neck surgery-otolaryngology","first-page":"1666","author":"Hall","year":"2001"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0745","first-page":"157","article-title":"Chapter 11 - audiometry and other hearing tests","volume":"vol. 137","author":"Davies","year":"2016"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0750","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1682\/JRRD.2011.11.0225","article-title":"Characteristics of the audiometric 4,000 Hz notch (744,553 veterans) and the 3,000, 4,000, and 6,000 Hz notches (539,932 veterans)","volume":"50","author":"Wilson","year":"2013","journal-title":"J Rehabil Res Dev"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0755","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a035493","article-title":"Hidden hearing loss: A disorder with multiple etiologies and mechanisms","volume":"10","author":"Kohrman","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0760","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1121\/1.1907229","article-title":"Some experiments on the recognition of speech, with one and with two ears","volume":"25","author":"Cherry","year":"1953","journal-title":"J Acoust Soc Am"},{"year":"1994","series-title":"Auditory scene analysis: the perceptual organization of sound","author":"Bregman","key":"10.1016\/bs.pmch.2022.05.001_bb0765"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0770","series-title":"Handbook of clinical neurophysiology","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/B978-0-7020-5310-8.00006-5","article-title":"Chapter 6 - otoacoustic emissions","volume":"vol. 10","author":"Lonsbury-Martin","year":"2013"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0775","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"4577","key":"10.1016\/bs.pmch.2022.05.001_bb0780","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1126\/science.6890712","article-title":"New chemistry of an old molecule: cis-[Pt(NH3)2Cl2]","volume":"218","author":"Lippard","year":"1982","journal-title":"Science (New York, NY)"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb0785","article-title":"Association of Sodium Thiosulfate with Risk of ototoxic effects from platinum-based chemotherapy","volume":"4","author":"Chen","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb0790","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1039\/c2mt20076g","article-title":"The effect of sodium thiosulfate on the metabolism of cis-platin in human plasma in vitro","volume":"4","author":"Sooriyaarachchi","year":"2012","journal-title":"Metallomics"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb0795","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF00257119","article-title":"Sodium thiosulfate inhibits cis-diamminedichloroplatinum (II) activity","volume":"13","author":"Uozumi","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0800","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jinorgbio.2016.06.012","article-title":"Chemical basis for the detoxification of cisplatin-derived hydrolysis products by sodium thiosulfate","volume":"162","author":"Sooriyaarachchi","year":"2016","journal-title":"J Inorg Biochem"},{"issue":"25","key":"10.1016\/bs.pmch.2022.05.001_bb0805","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1056\/NEJMoa1801109","article-title":"Sodium thiosulfate for protection from cisplatin-induced hearing loss","volume":"378","author":"Brock","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0810","unstructured":"FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARK\u2122 [press release]. 2020."},{"key":"10.1016\/bs.pmch.2022.05.001_bb0815","unstructured":"Lee CM, Lovelace TC, Moore JA, III, Kirschner DL, Fennec Pharmaceuticals, Inc., USA. Formulations of anhydrous sodium thiosulfate for treating ototoxicity. WO2020009954A1. 2020."},{"key":"10.1016\/bs.pmch.2022.05.001_bb0820","unstructured":"Lovelace TC, Moore JA, III, Lee CM, Kirschner DL, Fennec Pharmaceuticals, Inc., USA. Anhydrous sodium thiosulfate and formulations thereof. WO2020009953A1. 2020."},{"issue":"12","key":"10.1016\/bs.pmch.2022.05.001_bb0825","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJMc1809501","article-title":"Sodium thiosulfate and cisplatin-induced hearing loss","volume":"379","author":"Freyer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0830","unstructured":"Lee J, Soglia JR, Hu Q-Y, Shi F, Decibel Therapeutics, Inc., USA. Methods of otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt. US10813947B1. 2020."},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0835","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s10637-020-00918-1","article-title":"Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients","volume":"38","author":"Viglietta","year":"2020","journal-title":"Invest New Drugs"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb0840","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110979","article-title":"Apaf-1 inhibitors protect from unwanted cell death in in vivo models of kidney ischemia and chemotherapy induced ototoxicity","volume":"9","author":"Orz\u00e1ez","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb0845","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.363","article-title":"Therapeutic efficiency of the APAF-1 antagonist LPT99 in a rat model of cisplatin-induced hearing loss","volume":"11","author":"Murillo-Cuesta","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0850","unstructured":"Messeguer Peypoch A, Moure Fernandez A, Gonzalez Pinacho D, Masip Masip I, Perez Paya E, Garcia Villar N, et al., Laboratorios SALVAT, S.A., Spain. Preparation of 2,5-piperazinedione peptidomimetics as Apaf-1 inhibitors. WO2011012746A2. 2011."},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0855","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/bs.pmch.2022.05.001_bb0860","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/ci500467k","article-title":"iLOGP: A simple, robust, and efficient description of n-octanol\/Water partition coefficient for drug design using the GB\/SA approach","volume":"54","author":"Daina","year":"2014","journal-title":"J Chem Inf Model"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb0865","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb0870","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous system multiparameter optimization desirability: application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem Nerosci"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb0875","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrd3187-c1","article-title":"Understanding transport through pharmacological barriers \u2014 are we there yet?","volume":"9","author":"Sarkadi","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb0880","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","article-title":"The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME\u2013tox)","volume":"13","author":"Szak\u00e1cs","year":"2008","journal-title":"Drug Discov Today"},{"issue":"Pt 2","key":"10.1016\/bs.pmch.2022.05.001_bb0885","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1113\/jphysiol.2005.085951","article-title":"The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels","volume":"567","author":"Marcotti","year":"2005","journal-title":"J Physiol"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb0890","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1021\/acs.jmedchem.8b01325","article-title":"Design, synthesis, and biological evaluation of a new series of carvedilol derivatives that protect sensory hair cells from aminoglycoside-induced damage by blocking the mechanoelectrical Transducer Channel","volume":"62","author":"O'Reilly","year":"2019","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/bs.pmch.2022.05.001_bb0895","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1523\/JNEUROSCI.21-18-07013.2001","article-title":"FM1-43 dye behaves as a permeant blocker of the hair-cell Mechanotransducer Channel","volume":"21","author":"Gale","year":"2001","journal-title":"J Neurosci"},{"issue":"15","key":"10.1016\/bs.pmch.2022.05.001_bb0900","article-title":"ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity. JCI","volume":"4","author":"Kitcher","year":"2019","journal-title":"Insight"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb0905","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10162-002-3022-x","article-title":"Neomycin-induced hair cell death and rapid regeneration in the lateral line of zebrafish (Danio rerio)","volume":"4","author":"Harris","year":"2003","journal-title":"J Assoc Res Otolaryngol"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000020","article-title":"Identification of genetic and chemical modulators of zebrafish mechanosensory hair cell death","volume":"4","author":"Owens","year":"2008","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0915","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/zeb.2009.0639","article-title":"Chemical screening for hair cell loss and protection in the zebrafish lateral line","volume":"7","author":"Coffin","year":"2010","journal-title":"Zebrafish"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb0920","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.biolcel.2003.10.005","article-title":"The lateral line of zebrafish: a model system for the analysis of morphogenesis and neural development in vertebrates","volume":"95","author":"Dambly-Chaudi\u00e8re","year":"2003","journal-title":"Biol Cell"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb0925","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0378-5955(03)00259-4","article-title":"Developmental differences in susceptibility to neomycin-induced hair cell death in the lateral line neuromasts of zebrafish (Danio rerio)","volume":"186","author":"Murakami","year":"2003","journal-title":"Hear Res"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb0930","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.heares.2005.12.009","article-title":"Lateral line hair cell maturation is a determinant of aminoglycoside susceptibility in zebrafish (Danio rerio)","volume":"213","author":"Santos","year":"2006","journal-title":"Hear Res"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb0935","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-5955(00)00039-3","article-title":"Cell turnover in neuromasts of zebrafish larvae","volume":"143","author":"Williams","year":"2000","journal-title":"Hear Res"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb0940","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.heares.2007.07.003","article-title":"Cisplatin-induced hair cell loss in zebrafish (Danio rerio) lateral line","volume":"233","author":"Ou","year":"2007","journal-title":"Hear Res"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb0945","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.heares.2005.05.005","article-title":"The use of zebrafish for assessing ototoxic and otoprotective agents","volume":"208","author":"Ton","year":"2005","journal-title":"Hear Res"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0950","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/acs.jmedchem.7b00932","article-title":"Phenotypic optimization of urea-thiophene carboxamides to yield potent, well tolerated, and orally active protective agents against aminoglycoside-induced hearing loss","volume":"61","author":"Chowdhury","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb0955","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/047002142X.ch10","article-title":"HERG block QT liability and sudden cardiac death","volume":"266","author":"Brown","year":"2005","journal-title":"Novartis Found Symp"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb0960","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1755-5922.2010.00154.x","article-title":"Drug-induced hERG block and long QT syndrome","volume":"29","author":"Witchel","year":"2011","journal-title":"Cardiovasc Ther"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb0965","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/11050371","article-title":"First synthesis of 3-acetyl-2-aminothiophenes using the Gewald reaction","volume":"11","author":"Eller","year":"2006","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb0970","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11030-010-9229-6","article-title":"The Gewald multicomponent reaction","volume":"15","author":"Huang","year":"2011","journal-title":"Mol Divers"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb0975","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov Today"},{"issue":"21","key":"10.1016\/bs.pmch.2022.05.001_bb0980","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1016\/j.bmcl.2013.08.029","article-title":"Setting expectations in molecular optimizations: strengths and limitations of commonly used composite parameters","volume":"23","author":"Shultz","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb0985","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem Nerosci"},{"year":"2022","series-title":"Oricula therapeutics product history","author":"Oricula_Therapeutics","key":"10.1016\/bs.pmch.2022.05.001_bb0990"},{"year":"2017","series-title":"Decibel therapeutics and Oricula therapeutics announce exclusive license for ORC-13661 in phase 1 development for hearing and balance protection 2017","author":"Oricula_Therapeutics","key":"10.1016\/bs.pmch.2022.05.001_bb0995"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1000","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10162-009-0158-y","article-title":"Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) utricle","volume":"10","author":"Ou","year":"2009","journal-title":"J Assoc Res Otolaryngol"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1005","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10162-012-0353-0","article-title":"Quinoline Ring derivatives protect against aminoglycoside-induced hair cell death in the zebrafish lateral line","volume":"13","author":"Ou","year":"2012","journal-title":"J Assoc Res Otolaryngol"},{"issue":"262","key":"10.1016\/bs.pmch.2022.05.001_bb1010","article-title":"D-tubocurarine and Berbamine: alkaloids that are permeant blockers of the hair Cell's Mechano-electrical Transducer Channel and protect from aminoglycoside toxicity","volume":"11","author":"Kirkwood","year":"2017","journal-title":"Front Cell Neurosci"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb1015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145704","article-title":"Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity","volume":"6","author":"Kenyon","year":"2021","journal-title":"JCI Insight"},{"issue":"24","key":"10.1016\/bs.pmch.2022.05.001_bb1020","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96773","article-title":"Identification of ion-channel modulators that protect against aminoglycoside-induced hair cell death","volume":"2","author":"Kenyon","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1025","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38433","article-title":"Structural relationship between the putative hair cell mechanotransduction channel TMC1 and TMEM16 proteins","volume":"7","author":"Ballesteros","year":"2018","journal-title":"Elife"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1030","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.neuron.2018.07.033","article-title":"TMC1 forms the pore of mechanosensory transduction channels in vertebrate inner ear hair cells","volume":"99","author":"Pan","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1035","article-title":"Towards the prevention of aminoglycoside-related hearing loss","volume":"11","author":"O'Sullivan","year":"2017","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1021\/acs.jmedchem.7b01645","article-title":"Mind your ears: A new antidote to aminoglycoside toxicity?","volume":"61","author":"O'Sullivan","year":"2018","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb1045","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/cber.19240570703","article-title":"\u00dcber selenhaltige aromatische Verbindungen (VI)","volume":"57","author":"Lesser","year":"1924","journal-title":"Ber Dtsch Chem Ges (A and B Series)"},{"issue":"14","key":"10.1016\/bs.pmch.2022.05.001_bb1050","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.3390\/molecules26144230","article-title":"Ebselen and analogues: pharmacological properties and synthetic strategies for their preparation","volume":"26","author":"Santi","year":"2021","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/bs.pmch.2022.05.001_bb1055","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1021\/ol102027j","article-title":"Cu-catalyzed efficient synthetic methodology for Ebselen and related Se\u2212N heterocycles","volume":"12","author":"Balkrishna","year":"2010","journal-title":"Org Lett"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb1060","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1246\/bcsj.59.2179","article-title":"Photochemical reaction of 2-aryl-1,2-benzisoselenazol-3(2H)-ones","volume":"59","author":"Kamigata","year":"1986","journal-title":"Bull Chem Soc Jpn"},{"issue":"12","key":"10.1016\/bs.pmch.2022.05.001_bb1065","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1021\/jo00273a035","article-title":"Expedient synthesis of ebselen and related compounds","volume":"54","author":"Engman","year":"1989","journal-title":"J Org Chem"},{"issue":"20","key":"10.1016\/bs.pmch.2022.05.001_bb1070","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1016\/0006-2952(84)90083-2","article-title":"A novel biologically active seleno-organic compound\u20141: glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen)","volume":"33","author":"M\u00fcller","year":"1984","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0891-5849(93)90028-S","article-title":"Ebselen, a selenoorganic compound as glutathione peroxidase mimic","volume":"14","author":"Sies","year":"1993","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1080","first-page":"476","article-title":"[47] Ebselen: A glutathione peroxidase mimic","volume":"vol. 234","author":"Sies","year":"1994"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb1085","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/tx0601105","article-title":"Ebselen, a seleno-organic antioxidant, as an electrophile","volume":"19","author":"Sakurai","year":"2006","journal-title":"Chem Res Toxicol"},{"issue":"20","key":"10.1016\/bs.pmch.2022.05.001_bb1090","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1016\/0006-2952(84)90085-6","article-title":"A novel biologically active seleno-organic compound\u2014III: effects of PZ 51 (ebselen) on glutathione peroxidase and secretory activities of mouse macrophages","volume":"33","author":"Parnham","year":"1984","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb1095","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.bcp.2013.08.028","article-title":"The early research and development of ebselen","volume":"86","author":"Parnham","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"32","key":"10.1016\/bs.pmch.2022.05.001_bb1100","doi-asserted-by":"crossref","first-page":"11477","DOI":"10.1021\/ja052794t","article-title":"Glutathione peroxidase (GPx)-like antioxidant activity of the Organoselenium drug Ebselen: unexpected complications with thiol exchange reactions","volume":"127","author":"Sarma","year":"2005","journal-title":"J Am Chem Soc"},{"issue":"38","key":"10.1016\/bs.pmch.2022.05.001_bb1105","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1016\/j.tet.2018.05.027","article-title":"Key steps and intermediates in the catalytic mechanism for the reduction of peroxides by the antioxidant ebselen","volume":"74","author":"Sands","year":"2018","journal-title":"Tetrahedron"},{"issue":"23","key":"10.1016\/bs.pmch.2022.05.001_bb1110","doi-asserted-by":"crossref","first-page":"12075","DOI":"10.1021\/ic201603v","article-title":"Modeling the mechanism of the glutathione peroxidase mimic Ebselen","volume":"50","author":"Antony","year":"2011","journal-title":"Inorg Chem"},{"issue":"34","key":"10.1016\/bs.pmch.2022.05.001_bb1115","doi-asserted-by":"crossref","first-page":"10603","DOI":"10.1002\/chem.200801258","article-title":"Antioxidant activity of the anti-inflammatory compound Ebselen: A reversible cyclization pathway via Selenenic and Seleninic acid intermediates","volume":"14","author":"Sarma","year":"2008","journal-title":"Chem A Eur J"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb1120","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1007\/s11033-014-3417-x","article-title":"Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways","volume":"41","author":"Azad","year":"2014","journal-title":"Mol Biol Rep"},{"issue":"23","key":"10.1016\/bs.pmch.2022.05.001_bb1125","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.4155\/fmc-2019-0218","article-title":"Mechanisms of ebselen as a therapeutic and its pharmacology applications","volume":"12","author":"Wang","year":"2020","journal-title":"Future Med Chem"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00204-021-03003-5","article-title":"Toxicology and pharmacology of synthetic organoselenium compounds: an update","volume":"95","author":"Nogueira","year":"2021","journal-title":"Arch Toxicol"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1135","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1021\/acs.jmedchem.1c01859","article-title":"Incorporating selenium into heterocycles and natural productsfrom chemical properties to pharmacological activities","volume":"65","author":"Hou","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1140","article-title":"Development of ebselen for the treatment of sensorineural hearing loss and tinnitus","volume":"108209","author":"Kil","year":"2021","journal-title":"Hear Res"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1145","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0006-2952(94)90150-3","article-title":"Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte","volume":"48","author":"Wagner","year":"1994","journal-title":"Biochem Pharmacol"},{"year":"1989","series-title":"Binding of Ebselen to plasma protein","key":"10.1016\/bs.pmch.2022.05.001_bb1150"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0006-2952(96)00109-8","article-title":"Ebselen-binding equilibria between plasma and target proteins","volume":"52","author":"Ullrich","year":"1996","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/bs.pmch.2022.05.001_bb1160","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3109\/00498258809042259","article-title":"A novel biologically active Selenoorganic compound. VIII. Biotransformation of Ebselen","volume":"18","author":"Fischer","year":"1988","journal-title":"Xenobiotica"},{"year":"1989","series-title":"Metabolism and disposition of ebselen","key":"10.1016\/bs.pmch.2022.05.001_bb1165"},{"issue":"01","key":"10.1016\/bs.pmch.2022.05.001_bb1170","doi-asserted-by":"crossref","first-page":"047","DOI":"10.1055\/s-0028-1111106","article-title":"Development of Ebselen, a glutathione peroxidase mimic, for the prevention and treatment of noise-induced hearing loss","volume":"30","author":"Lynch","year":"2009","journal-title":"Semin Hear"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s101620010043","article-title":"Targeted mutation of the gene for cellular glutathione peroxidase (Gpx1) increases noise-induced hearing loss in mice","volume":"1","author":"Ohlemiller","year":"2000","journal-title":"J Assoc Res Otolaryngol"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1180","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0378-5955(03)00178-3","article-title":"Ebselen attenuates cochlear damage caused by acoustic trauma","volume":"181","author":"Pourbakht","year":"2003","journal-title":"Hear Res"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb1185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.heares.2006.08.006","article-title":"Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase","volume":"226","author":"Kil","year":"2007","journal-title":"Hear Res"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1190","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00005537-200402000-00029","article-title":"Ebselen-mediated protection from single and repeated noise exposure in rat","volume":"114","author":"Lynch","year":"2004","journal-title":"Laryngoscope"},{"issue":"10098","key":"10.1016\/bs.pmch.2022.05.001_bb1195","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0140-6736(17)31791-9","article-title":"Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"390","author":"Kil","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.heares.2004.08.002","article-title":"Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen","volume":"201","author":"Lynch","year":"2005","journal-title":"Hear Res"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb1205","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00001813-200506000-00013","article-title":"Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity","volume":"16","author":"Lynch","year":"2005","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2020.02.014","article-title":"Ebselen attenuates tobramycin-induced ototoxicity in mice","volume":"20","author":"Gu","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"961","key":"10.1016\/bs.pmch.2022.05.001_bb1215","article-title":"A novel mouse model of aminoglycoside-induced hyperacusis and tinnitus","volume":"14","author":"Longenecker","year":"2020","journal-title":"Front Neurosci"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000027643","article-title":"Free radicals in the Guinea pig inner ear following gentamicin exposure","volume":"61","author":"Takumida","year":"1999","journal-title":"ORL"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb1225","first-page":"559","article-title":"Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells","volume":"18","author":"Kopke","year":"1997","journal-title":"Am J Otol"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1230","first-page":"513","article-title":"Effect of protective agents against cisplatin ototoxicity","volume":"21","author":"Rybak","year":"2000","journal-title":"Am J Otol"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb1235","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1097\/00005537-199911000-00003","article-title":"Application of antioxidants and other agents to prevent cisplatin ototoxicity","volume":"109","author":"Rybak","year":"1999","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1240","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.heares.2009.03.003","article-title":"Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells","volume":"251","author":"Kim","year":"2009","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1245","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.heares.2018.03.003","article-title":"Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)","volume":"368","author":"Eshraghi","year":"2018","journal-title":"Hear Res"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1250","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0092-8674(88)90263-2","article-title":"Cellular uptake of the tat protein from human immunodeficiency virus","volume":"55","author":"Frankel","year":"1988","journal-title":"Cell"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1255","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0092-8674(88)90262-0","article-title":"Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein","volume":"55","author":"Green","year":"1988","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1260","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drudis.2014.09.017","article-title":"Therapeutic applications of the cell-penetrating HIV-1 tat peptide","volume":"20","author":"Rizzuti","year":"2015","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1265","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00232-016-9940-z","article-title":"Progress in research and application of HIV-1 TAT-derived cell-penetrating peptide","volume":"250","author":"Zou","year":"2017","journal-title":"J Membr Biol"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb1270","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17425247.2019.1676720","article-title":"Cell penetrating peptides: the potent multi-cargo intracellular carriers","volume":"16","author":"Kardani","year":"2019","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1275","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/14712598.2021.1823368","article-title":"Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics","volume":"21","author":"Kurrikoff","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1280","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000241892","article-title":"Principles of local drug delivery to the inner ear","volume":"14","author":"Salt","year":"2009","journal-title":"Audiol Neurotol"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1285","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1124\/mol.106.028936","article-title":"Inhibition of the c-Jun N-terminal kinase-mediated mitochondrial cell death pathway restores auditory function in sound-exposed animals","volume":"71","author":"Wang","year":"2007","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb1290","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/MAO.0000000000002229","article-title":"Efficacy and safety of AM-111 in the treatment of acute unilateral sudden deafness\u2014A double-blind, randomized, placebo-controlled phase 3 study","volume":"40","author":"Staecker","year":"2019","journal-title":"Otol Neurotol"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1295","first-page":"37","article-title":"Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones","volume":"40","author":"Sohda","year":"1990","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1300","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1305","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-3233(01)56006-4","article-title":"Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes","volume":"56","author":"Moller","year":"2001","journal-title":"Adv Protein Chem"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb1315","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1517\/14656566.9.7.1087","article-title":"Pleiotropic effects of thiazolidinediones","volume":"9","author":"Rizos","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb1320","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/ph14101025","article-title":"Repurposing peroxisome proliferator-activated receptor agonists in neurological and psychiatric disorders","volume":"14","author":"Sagheddu","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"58","key":"10.1016\/bs.pmch.2022.05.001_bb1325","article-title":"Mechanisms of sensorineural cell damage, death and survival in the cochlea","volume":"7","author":"Wong","year":"2015","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1330","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/00016489509121877","article-title":"The emergence of free radicals after acoustic trauma and strial blood flow","volume":"519","author":"Yamane","year":"1995","journal-title":"Acta Otolaryngol Suppl"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb1335","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000013846","article-title":"Early elevation of Cochlear reactive oxygen species following noise exposure","volume":"4","author":"Ohlemiller","year":"1999","journal-title":"Audiol Neurootol"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-8993(02)04090-8","article-title":"Upregulated iNOS and oxidative damage to the cochlear stria vascularis due to noise stress","volume":"967","author":"Shi","year":"2003","journal-title":"Brain Res"},{"issue":"2\u20133","key":"10.1016\/bs.pmch.2022.05.001_bb1345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0736-5748(99)00094-5","article-title":"Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotective strategies","volume":"18","author":"Huang","year":"2000","journal-title":"Int J Dev Neurosci"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb1350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188596","article-title":"Effects of peroxisome proliferator activated receptors (PPAR)-\u03b3 and -a agonists on cochlear protection from oxidative stress","volume":"12","author":"Sekulic-Jablanovic","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1355","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2019.02.022","article-title":"Targeting dysregulation of redox homeostasis in noise-induced hearing loss: oxidative stress and ROS signaling","volume":"135","author":"Fetoni","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"1103","key":"10.1016\/bs.pmch.2022.05.001_bb1360","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3389\/fphar.2018.01103","article-title":"Pioglitazone represents an effective therapeutic target in preventing oxidative\/inflammatory Cochlear damage induced by noise exposure","volume":"9","author":"Paciello","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1365","first-page":"27","article-title":"Safety profile of pioglitazone","volume":"121","author":"Hanefeld","year":"2001","journal-title":"Int J Clin Pract Suppl"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1370","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00280-013-2084-2","article-title":"The PPAR\u03b3 agonist pioglitazone crosses the blood\u2013brain barrier and reduces tumor growth in a human xenograft model","volume":"71","author":"Grommes","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1375","first-page":"29","article-title":"Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys","volume":"47","author":"Maeshiba","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1380","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-2094-8-91","article-title":"The PPAR-\u03b3 agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys","volume":"8","author":"Swanson","year":"2011","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1385","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1038\/srep09000","article-title":"Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease","volume":"5","author":"Chang","year":"2015","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/bs.pmch.2022.05.001_bb1390","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1021\/acs.jmedchem.5b00552","article-title":"Effect of chirality on common in vitro experiments: an enantiomeric pair analysis","volume":"58","author":"Bagdanoff","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1395","unstructured":"Bausch A, Support-Venture GmbH, Switz. Method of preventing or treating hearing loss using peroxisome proliferator-activated receptor (PPAR) agonists. WO2016128438A1. 2016."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1400","unstructured":"Bausch A, Zeller M, Strekin AG, Switz. Gel formulation for preventing or treating hearing loss. WO2019154895A1. 2019."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1405","unstructured":"Bausch A, Zeller M, Strekin AG, Switz. Oral extended release pharmaceutical compositions for preventing or treating hearing loss. WO2019154893A1. 2019."},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb1410","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2165\/00003495-199345050-00010","article-title":"Zonisamide","volume":"45","author":"Peters","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1415","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.seizure.2004.04.016","article-title":"Zonisamide: chemistry, mechanism of action, and pharmacokinetics","volume":"13","author":"Leppik","year":"2004","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb1420","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2019.1595584","article-title":"An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy","volume":"20","author":"Reimers","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"1315","key":"10.1016\/bs.pmch.2022.05.001_bb1425","article-title":"Zonisamide for the treatment of Parkinson disease: A current update","volume":"14","author":"Li","year":"2020","journal-title":"Front Neurosci"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1430","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/jm00188a011","article-title":"Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities","volume":"22","author":"Uno","year":"1979","journal-title":"J Med Chem"},{"issue":"25","key":"10.1016\/bs.pmch.2022.05.001_bb1435","article-title":"ChemInform abstract: STUDIES ON 3-SUBSTITUTED 1,2-BENZISOXAZOLE DERIVATIVES. 6. SYNTHESES OF 3-(SULFAMOYLMETHYL)-1,2-BENZISOXAZOLE DERIVATIVES AND THEIR ANTICONVULSANT ACTIVITIES","volume":"10","author":"Uno","year":"1979","journal-title":"Chem Inf-Dienst"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb1440","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.bmcl.2005.03.032","article-title":"Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies","volume":"15","author":"Simone","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1445","first-page":"477","article-title":"3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile","volume":"30","author":"Masuda","year":"1980","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1450","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-020-02786-z","article-title":"Pre-clinical assessment of the nose-to-brain delivery of Zonisamide after intranasal administration","volume":"37","author":"Gon\u00e7alves","year":"2020","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1455","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1528-1167.2007.00983.x","article-title":"Pharmacokinetics and drug interactions with Zonisamide","volume":"48","author":"Sills","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1460","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.heares.2013.06.004","article-title":"Prophylactic and therapeutic functions of drug combinations against noise-induced hearing loss","volume":"304","author":"Bao","year":"2013","journal-title":"Hear Res"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1465","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MAO.0000000000002088","article-title":"SENS-401 effectively reduces severe acoustic trauma-induced hearing loss in male rats with twice daily administration delayed up to 96 hours","volume":"40","author":"Petremann","year":"2019","journal-title":"Otol Neurotol"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb1470","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1097\/MAO.0000000000001546","article-title":"Oral Administration of Clinical Stage Drug Candidate SENS-401 effectively reduces cisplatin-induced hearing loss in rats","volume":"38","author":"Petremann","year":"2017","journal-title":"Otol Neurotol"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1475","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1248\/cpb.40.624","article-title":"Synthesis and pharmacology of 3, 4-Dihydro-3-oxo-1, 4-benzoxazine-8-carboxamide derivatives, a new class of potent Serotonin-3 (5-HT<SUB>3<\/SUB>) receptor antagonists","volume":"40","author":"Kwakita","year":"1992","journal-title":"Chem Pharm Bull"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1480","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(91)90443-T","article-title":"The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist","volume":"196","author":"Takemi","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1485","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.heares.2018.11.013","article-title":"Noise-induced trauma produces a temporal pattern of change in blood levels of the outer hair cell biomarker prestin","volume":"371","author":"Parham","year":"2019","journal-title":"Hear Res"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb1490","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0969-8043(95)00147-6","article-title":"Synthesis of 5-HT3 receptor antagonists, [11C]Y-25130 and [11C]YM060","volume":"46","author":"Ishiwata","year":"1995","journal-title":"Appl Radiat Isot"},{"year":"2017","series-title":"(+)-Azasetron for use in the treatment of ear disorders","author":"Dyhrfjeld-Johnsen","key":"10.1016\/bs.pmch.2022.05.001_bb1495"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1500","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/S0021-9258(19)39919-3","article-title":"Identification of an autoinhibitory domain in calcineurin","volume":"265","author":"Hashimoto","year":"1990","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-0082(98)00073-2","article-title":"Potential role of calcineurin for brain ischemia and traumatic injury","volume":"58","author":"Morioka","year":"1999","journal-title":"Prog Neurobiol"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1510","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/jnr.20267","article-title":"Calcineurin activation contributes to noise-induced hearing loss","volume":"78","author":"Minami","year":"2004","journal-title":"J Neurosci Res"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb1515","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.heares.2005.06.010","article-title":"Protective effect of calcineurin inhibitors on acoustic injury of the cochlea","volume":"209","author":"Uemaetomari","year":"2005","journal-title":"Hear Res"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1520","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1111\/j.1476-5381.2012.01890.x","article-title":"Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses","volume":"166","author":"Bas","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"435","key":"10.1016\/bs.pmch.2022.05.001_bb1525","article-title":"Treatment with calcineurin inhibitor FK506 attenuates noise-induced hearing loss","volume":"9","author":"He","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1530","unstructured":"Rommelspacher H, Enzensperger C, AudioCure Pharma GmbH, Germany. Preparation of fluoro-substituted-9-methyl-\u03b2-carbolines for the treatment of ear diseases. WO2015044434A2. 2015."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1535","unstructured":"Rommelspacher H, Zygmunt T, Schlingensiepen R, Audiocure Pharma GmbH, Germany. Stable polymorphic form of 6-fluoro-9-methyl-9H-\u03b2-carboline and uses thereof. WO2021028365A1. 2021."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1540","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/617207","article-title":"Reactive oxygen species, apoptosis, and mitochondrial dysfunction in hearing loss","volume":"2015","author":"Kamogashira","year":"2015","journal-title":"Biomed Res Int"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb1545","article-title":"Mitochondrial glutathione: recent insights and role in disease","volume":"9","author":"Mar\u00ed","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1550","first-page":"205","article-title":"N-Acetylcystei ne: pharmacological considerations and experimental and clinical applications","volume":"vol. 38","author":"Cotgreave","year":"1996"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1555","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.heares.2015.01.002","article-title":"Efficacy and safety of N-acetylcysteine in prevention of noise induced hearing loss: A randomized clinical trial","volume":"323","author":"Kopke","year":"2015","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1560","article-title":"Effect of N-acetyl-cysteine treatment on sensorineural hearing loss: A meta-analysis","author":"Bai","year":"2021","journal-title":"World J Otorhinolaryngol - Head Neck Surg"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1565","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1161\/STROKEAHA.107.503334","article-title":"NXY-059 for the treatment of acute stroke","volume":"39","author":"Diener","year":"2008","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1570","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMoa070240","article-title":"NXY-059 for the treatment of acute ischemic stroke","volume":"357","author":"Shuaib","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb1575","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1161\/STROKEAHA.108.515957","article-title":"Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality","volume":"39","author":"Macleod","year":"2008","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb1580","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1046\/j.1471-4159.2003.01580.x","article-title":"The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice","volume":"84","author":"Farr","year":"2003","journal-title":"J Neurochem"},{"issue":"5","key":"10.1016\/bs.pmch.2022.05.001_bb1585","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.parkreldis.2015.02.020","article-title":"Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease","volume":"21","author":"Katz","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1590","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa052980","article-title":"NXY-059 for acute ischemic stroke","volume":"354","author":"Lees","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb1595","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00004647-199907000-00008","article-title":"Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat","volume":"19","author":"Kuroda","year":"1999","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1600","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-8993(02)03469-8","article-title":"In vitro blood\u2013brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions","volume":"955","author":"Dehouck","year":"2002","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1605","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10162-014-0441-4","article-title":"Antioxidants reduce cellular and functional changes induced by intense noise in the inner ear and Cochlear nucleus","volume":"15","author":"Lu","year":"2014","journal-title":"J Assoc Res Otolaryngol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1610","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.711269","article-title":"Use of radical oxygen species scavenger nitrones to treat oxidative stress-mediated hearing loss: state of the art and challenges","volume":"15","author":"Varela-Nieto","year":"2021","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1615","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/10715760100300351","article-title":"Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059","volume":"34","author":"Maples","year":"2001","journal-title":"Free Radic Res"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb1620","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/10715760701557161","article-title":"Investigating the free radical trapping ability of NXY-059, S-PBN and PBN","volume":"41","author":"Williams","year":"2007","journal-title":"Free Radic Res"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1625","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/med.21461","article-title":"NO and HNO donors, nitrones, and nitroxides: past, present, and future","volume":"38","author":"Oliveira","year":"2018","journal-title":"Med Res Rev"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb1630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183089","article-title":"HPN-07, a free radical spin trapping agent, protects against functional, cellular and electrophysiological changes in the cochlea induced by acute acoustic trauma","volume":"12","author":"Ewert","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1635","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.heares.2012.01.013","article-title":"Antioxidant treatment reduces blast-induced cochlear damage and hearing loss","volume":"285","author":"Ewert","year":"2012","journal-title":"Hear Res"},{"issue":"18","key":"10.1016\/bs.pmch.2022.05.001_bb1640","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.2174\/1568026617666170303115324","article-title":"Nitrone derivatives as therapeutics: from chemical modification to specific-targeting","volume":"17","author":"Rosselin","year":"2017","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1645","unstructured":"Carney JM, Oklahoma Medical Research Foundation, USA; University of Kentucky Research Foundation. 2,4-Disulfonylphenyl tert-butyl nitrone and its salts as pharmaceutical free radical-trapping agents. ZA9504297A. 1996."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1650","unstructured":"Blixt J, Kruk H, Larsson U, McGinley J, Pouhov S, Vajda J, et al., AstraZeneca AB, Swed.; Centaur Pharmaceuticals, Inc. Preparation of \u03b1-(2,4-disulfophenyl)-N-tert-butylnitrone and pharmaceutically acceptable salts thereof. WO2001051461A1. 2001."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1655","unstructured":"Blixt J, Kruk H, McGinley J, Pouhov S, Vajda J, AstraZeneca AB, Swed.; Centaur Pharmaceuticals, Inc. Preparation of \u03b1-(2,4-disulfophenyl)-N-tert-butylnitrone and pharmaceutically acceptable salts thereof. WO2001051460A1. 2001."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1660","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1665","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/dot.2009.45.6.1378935","article-title":"Rilonacept in the treatment of chronic inflammatory disorders","volume":"45","author":"McDermott","year":"2009","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1670","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0378-5955(99)00187-2","article-title":"Differential expression of voltage-gated potassium channel genes in auditory nuclei of the mouse brainstem","volume":"140","author":"Grigg","year":"2000","journal-title":"Hear Res"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1675","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.heares.2011.10.008","article-title":"Acoustic over-exposure triggers burst firing in dorsal cochlear nucleus fusiform cells","volume":"283","author":"Pilati","year":"2012","journal-title":"Hear Res"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1680","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1179\/016164105X22011","article-title":"Age-related changes in the distribution of Kv1.1 and Kv3.1 in rat cochlear nuclei","volume":"27","author":"Jung","year":"2005","journal-title":"Neurol Res"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb1685","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1523\/JNEUROSCI.4554-03.2004","article-title":"Loss of Kv3.1 tonotopicity and alterations in cAMP response element-binding protein signaling in central auditory neurons of hearing impaired mice","volume":"24","author":"von Hehn","year":"2004","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1690","first-page":"280","article-title":"Age-related decline in Kv3.1b expression in the mouse auditory brainstem correlates with functional deficits in the medial olivocochlear efferent system. Journal for the Association for Research","volume":"8","author":"Zettel","year":"2007","journal-title":"Otolaryngology"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1695","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17406-x","article-title":"Pharmacological modulation of Kv3.1 mitigates auditory midbrain temporal processing deficits following auditory nerve damage","volume":"7","author":"Chambers","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1700","unstructured":"Alvaro G, Dambruoso P, Marasco A, Tommasi S, Decor A, Large C, Autifony Therapeutics Limited, UK. Preparation of hydantoin derivatives as Kv3 channel inhibitors. WO2012076877A1. 2012."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1705","unstructured":"Alvaro G, Decor A, Fontana S, Hamprecht D, Large C, Marasco A, Glaxo Group Limited, UK. Imidazolinedione derivatives as Kv3 potassium channel modulators and their preparation and use for the treatment of diseases. WO2011069951A1. 2011."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1710","unstructured":"Alvaro G, Decor A, Hamprecht D, Marasco A, Autifony Therapeutics Ltd., UK. Preparation of hydantoin derivatives for use as Kv3 inhibitors. WO2012168710A1. 2012."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1715","unstructured":"Alvaro G, Marasco A, Autifony Therapeutics Limited, UK. Preparation of hydantoin derivatives as Kv3 inhibitors. WO2013083994A1. 2013."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1720","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.heares.2018.04.012","article-title":"Increased spontaneous firing rates in auditory midbrain following noise exposure are specifically abolished by a Kv3 channel modulator","volume":"365","author":"Anderson","year":"2018","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1725","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2020.108139","article-title":"Effect of Kv3 channel modulators on auditory temporal resolution in aged Fischer 344 rats","volume":"401","author":"Rybalko","year":"2021","journal-title":"Hear Res"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1730","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/jpet.115.225748","article-title":"A novel modulator of Kv3 potassium channels regulates the firing of parvalbumin-positive cortical interneurons","volume":"354","author":"Rosato-Siri","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1735","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neuropharm.2018.02.004","article-title":"Kv3 K+ currents contribute to spike-timing in dorsal cochlear nucleus principal cells","volume":"133","author":"Olsen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1740","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejphar.2015.03.061","article-title":"Biophysical characterization of KV3.1 potassium channel activating compounds","volume":"758","author":"Taskin","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1745","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/npp.2017.155","article-title":"Antimanic efficacy of a novel Kv3 Potassium Channel modulator","volume":"43","author":"Parekh","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1750","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.heares.2019.03.018","article-title":"A balanced randomised placebo controlled blinded phase IIa multi-Centre study to investigate the efficacy and safety of AUT00063 versus placebo in subjective tinnitus: the QUIET-1 trial","volume":"377","author":"Hall","year":"2019","journal-title":"Hear Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1755","unstructured":"Alvaro G, Marasco A, Autifony Therapeutics Limited, UK. Pyrazinylimidazolidinediones as potassium channel Kv3.1, Kv3.2 and Kv3.3 modulators and their preparation. WO2020079422A1. 2020."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1760","unstructured":"Alvaro G, Marasco A, Autifony Therapeutics Limited, UK. Pyrazinylimidazolidinediones as potassium channel Kv3.1, Kv3.2 and Kv3.3 modulators and their preparation. WO2021156584A1. 2021."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1765","unstructured":"Alvaro G, Marasco A, Autifony Therapeutics Limited, UK. Hydantoins as modulators of Kv3 channels and their preparation. WO2018109484A1. 2018."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1770","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/j.euroneuro.2020.09.610","article-title":"P.847AUT00206 improves speech in noise recognition in patients with schizophrenia","volume":"40","author":"Sanchez","year":"2020","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/bs.pmch.2022.05.001_bb1775","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.tins.2019.03.006","article-title":"Mechanisms of hair cell damage and repair","volume":"42","author":"Wagner","year":"2019","journal-title":"Trends Neurosci"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb1780","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1242\/dev.126.8.1581","article-title":"p27(Kip1) links cell proliferation to morphogenesis in the developing organ of Corti","volume":"126","author":"Chen","year":"1999","journal-title":"Development"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb1785","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nrn1987","article-title":"Regulation of cell fate in the sensory epithelia of the inner ear","volume":"7","author":"Kelley","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"5712","key":"10.1016\/bs.pmch.2022.05.001_bb1790","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1126\/science.1106642","article-title":"Proliferation of functional hair cells in vivo in the absence of the retinoblastoma protein","volume":"307","author":"Sage","year":"2005","journal-title":"Science (New York, NY)"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1795","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/ijms23010066","article-title":"Molecular pathways modulating sensory hair cell regeneration in adult mammalian cochleae: Progress and perspectives","volume":"23","author":"Rai","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4860","key":"10.1016\/bs.pmch.2022.05.001_bb1800","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.3381100","article-title":"Regeneration of sensory hair cells after acoustic trauma","volume":"240","author":"Corwin","year":"1988","journal-title":"Science (New York, NY)"},{"issue":"12","key":"10.1016\/bs.pmch.2022.05.001_bb1805","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/bies.20502","article-title":"The molecular basis of neurosensory cell formation in ear development: a blueprint for hair cell and sensory neuron regeneration?","volume":"28","author":"Fritzsch","year":"2006","journal-title":"Bioessays"},{"issue":"null","key":"10.1016\/bs.pmch.2022.05.001_bb1810","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.3381101","article-title":"Hair cell regeneration after acoustic trauma in adult Coturnix quail","volume":"240","author":"Ryals","year":"1988","journal-title":"Science (New York, NY)"},{"issue":"23","key":"10.1016\/bs.pmch.2022.05.001_bb1815","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1242\/dev.125.23.4645","article-title":"Cell fate choices and the expression of notch, Delta and serrate homologues in the chick inner ear: parallels with Drosophila sense-organ development","volume":"125","author":"Adam","year":"1998","journal-title":"Development"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1820","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1242\/dev.01589","article-title":"Two contrasting roles for notch activity in chick inner ear development: specification of prosensory patches and lateral inhibition of hair-cell differentiation","volume":"132","author":"Daudet","year":"2005","journal-title":"Development"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1825","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical notch signaling pathway: unfolding the activation mechanism","volume":"137","author":"Kopan","year":"2009","journal-title":"Cell"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1830","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.649205","article-title":"Therapeutic targeting of notch signaling: from Cancer to inflammatory disorders","volume":"9","author":"Allen","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"5421","key":"10.1016\/bs.pmch.2022.05.001_bb1835","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.284.5421.1837","article-title":"Math1: an essential gene for the generation of inner ear hair cells","volume":"284","author":"Bermingham","year":"1999","journal-title":"Science (New York, NY)"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1840","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cell.2020.12.036","article-title":"Breathing new life into the rational design of Alzheimer's therapeutics","volume":"184","author":"Dries","year":"2021","journal-title":"Cell"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1845","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-1-4939-1139-4_23","article-title":"Small molecules that inhibit notch signaling","volume":"1187","author":"De Kloe","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1850","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuron.2012.10.032","article-title":"Notch inhibition induces cochlear hair cell regeneration and recovery of hearing after acoustic trauma","volume":"77","author":"Mizutari","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1855","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.710159","article-title":"Hair cell generation in Cochlear culture models mediated by novel \u03b3-secretase inhibitors","volume":"9","author":"Erni","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1860","unstructured":"Edge A, Okano H, Fujioka M, Mizutari K, Massachusetts Eye & Ear Infirmary, USA. Treating hearing loss using certain gamma secretase inhibitors. WO2014039781A1. 2014."},{"key":"10.1016\/bs.pmch.2022.05.001_bb1865","unstructured":"Clay JM, Edge A, Hipskind PA, Gill JC, Patel BK, Van Es HHG, et al., Eli Lilly and Company, USA; Audion Therapeutics. Pyridopyrroloazepines and benzopyrroloazepines as Notch pathway signaling inhibitors and their preparation. WO2017007702A1. 2017."},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1870","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1053\/j.gastro.2010.05.081","article-title":"Atonal homolog 1 is required for growth and differentiation effects of notch\/\u03b3-secretase inhibitors on Normal and cancerous intestinal epithelial cells","volume":"139","author":"Kazanjian","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1875","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1807581","article-title":"Hearing loss: reestablish the neural plasticity in regenerated spiral ganglion neurons and sensory hair cells","volume":"2017","author":"Chai","year":"2017","journal-title":"Neural Plast"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1880","doi-asserted-by":"crossref","DOI":"10.1016\/S0736-5748(96)00109-8","article-title":"Conditional immortalisation of hair cells from the inner ear","author":"Holley","year":"1997","journal-title":"Int J Dev Neurosci"},{"issue":"28","key":"10.1016\/bs.pmch.2022.05.001_bb1885","doi-asserted-by":"crossref","first-page":"9639","DOI":"10.1523\/JNEUROSCI.1064-12.2012","article-title":"Wnt-responsive Lgr5-expressing stem cells are hair cell progenitors in the cochlea","volume":"32","author":"Shi","year":"2012","journal-title":"J Neurosci"},{"issue":"34","key":"10.1016\/bs.pmch.2022.05.001_bb1890","doi-asserted-by":"crossref","first-page":"13851","DOI":"10.1073\/pnas.1219952110","article-title":"Generation of hair cells in neonatal mice by \u03b2-catenin overexpression in Lgr5-positive cochlear progenitors","volume":"110","author":"Shi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1895","unstructured":"McLean W, Frequency Therapeutics, Inc., USA. Methods for controlled proliferation of vestibular stem cells \/ generating inner ear hair cells using Wnt and TGF-\u03b2 inhibition. WO2017151909A2. 2017."},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1900","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1432-1033.1980.tb06059.x","article-title":"Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase","volume":"107","author":"Embi","year":"1980","journal-title":"Eur J Biochem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1905","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"167","key":"10.1016\/bs.pmch.2022.05.001_bb1910","article-title":"Recent advances in understanding the cellular roles of GSK-3 [version 1; peer review: 3 approved]","volume":"6","author":"Cormier","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1915","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.792364","article-title":"Glycogen synthase Kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward","volume":"14","author":"Arciniegas Ruiz","year":"2022","journal-title":"Front Mol Neurosci"},{"issue":"29","key":"10.1016\/bs.pmch.2022.05.001_bb1920","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.2174\/1381612823666170714141450","article-title":"GSK3 inhibitors in the therapeutic development of diabetes, Cancer and neurodegeneration: past, present and future","volume":"23","author":"Maqbool","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb1925","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14728222.2018.1526925","article-title":"Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging","volume":"22","author":"Duda","year":"2018","journal-title":"Expert Opin Ther Targets"},{"issue":"17","key":"10.1016\/bs.pmch.2022.05.001_bb1930","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.2174\/1568026620666200516153136","article-title":"Glycogen synthase kinase 3 (GSK3): its role and inhibitors","volume":"20","author":"Wadhwa","year":"2020","journal-title":"Curr Top Med Chem"},{"issue":"13","key":"10.1016\/bs.pmch.2022.05.001_bb1935","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2174\/1389450122666210118150313","article-title":"Anti-inflammatory potential of GSK-3 inhibitors","volume":"22","author":"Kandar","year":"2021","journal-title":"Curr Drug Targets"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb1940","doi-asserted-by":"crossref","first-page":"40716","DOI":"10.1038\/srep40716","article-title":"Activation of Wnt\/\u03b2-catenin signalling via GSK3 inhibitors direct differentiation of human adipose stem cells into functional hepatocytes","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb1945","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1574888X15666200621172042","article-title":"Advances in small molecules in cellular reprogramming: effects, structures, and mechanisms","volume":"16","author":"Zeng","year":"2021","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1950","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ejmech.2018.12.073","article-title":"Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3\u03b2 inhibitors: A critical review","volume":"164","author":"Xu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1955","unstructured":"Nuss JM, Harrison SD, Ring DB, Boyce RS, Brown SP, Goff D, et al., Chiron Corporation, USA. Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors. WO9965897A1. 1999."},{"issue":"20","key":"10.1016\/bs.pmch.2022.05.001_bb1960","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1021\/acs.jmedchem.7b00922","article-title":"Synthesis, binding mode, and antihyperglycemic activity of potent and selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine inhibitors of glycogen synthase kinase 3","volume":"60","author":"Wagman","year":"2017","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb1965","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2337\/diabetes.52.3.588","article-title":"Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo","volume":"52","author":"Ring","year":"2003","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb1970","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/npp.2011.24","article-title":"AKT kinase activity is required for Lithium to modulate mood-related behaviors in mice","volume":"36","author":"Pan","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 2","key":"10.1016\/bs.pmch.2022.05.001_bb1975","first-page":"17","article-title":"Pharmacology of valproate","volume":"37","author":"Owens","year":"2003","journal-title":"Psychopharmacol Bull"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb1980","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/metabo11110792","article-title":"Metabolism, HDACs, and HDAC inhibitors: A systems biology perspective","volume":"11","author":"King","year":"2021","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb1985","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1990","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112021","article-title":"Hidden pharmacological activities of valproic acid: A new insight","volume":"142","author":"Singh","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/bs.pmch.2022.05.001_bb1995","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2000","first-page":"19","article-title":"Chapter 2 - HDAC inhibitors in cancer therapy","volume":"vol. 20","author":"Ganesan","year":"2020"},{"issue":"21","key":"10.1016\/bs.pmch.2022.05.001_bb2005","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb2010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/17460441.2021.1877656","article-title":"An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives","volume":"16","author":"Su","year":"2021","journal-title":"Expert Opin Drug Discovery"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb2015","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/17460441.2020.1795125","article-title":"Lessons learned from the discovery of sodium valproate and what has this meant to future drug discovery efforts?","volume":"15","author":"Jankovi\u0107","year":"2020","journal-title":"Expert Opin Drug Discovery"},{"issue":"7","key":"10.1016\/bs.pmch.2022.05.001_bb2020","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/MLG.0b013e318058a06b","article-title":"Concentration gradient along the Scala tympani after local application of gentamicin to the round window membrane","volume":"117","author":"Plontke","year":"2007","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb2025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jneumeth.2005.10.008","article-title":"Perilymph sampling from the cochlear apex: a reliable method to obtain higher purity perilymph samples from scala tympani","volume":"153","author":"Salt","year":"2006","journal-title":"J Neurosci Methods"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2030","doi-asserted-by":"crossref","DOI":"10.1097\/MAO.0000000000003120","article-title":"Improved speech intelligibility in subjects with stable sensorineural hearing loss following intratympanic dosing of FX-322 in a phase 1b study","author":"McLean","year":"2021","journal-title":"Otol Neurotol"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb2035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000493846","article-title":"Dexamethasone and dexamethasone phosphate entry into perilymph compared for middle ear applications in Guinea pigs","volume":"23","author":"Salt","year":"2018","journal-title":"Audiol Neurootol"},{"issue":"8","key":"10.1016\/bs.pmch.2022.05.001_bb2040","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.celrep.2017.01.066","article-title":"Clonal expansion of Lgr5-positive cells from mammalian cochlea and high-purity generation of sensory hair cells","volume":"18","author":"McLean","year":"2017","journal-title":"Cell Rep"},{"year":"2022","series-title":"Pioneering a new category in regenerative medicine frequency therapeutics corporate presentation march","author":"Frequency Therapeutics","key":"10.1016\/bs.pmch.2022.05.001_bb2045"},{"issue":"20","key":"10.1016\/bs.pmch.2022.05.001_bb2050","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1021\/bi036072v","article-title":"Mechanism of gamma-secretase cleavage activation: is gamma-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop?","volume":"43","author":"Knappenberger","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2055","unstructured":"Loose C, Tait B, Manchanda R, McLean W, Frequency Therapeutics, Inc., USA. Use of pharmaceutical compositions comprising 1,5-dihydro-2H-pyrrol-2-one for inducing self-renewal of stem cells in injury repair. US20180214458A1. 2018."},{"key":"10.1016\/bs.pmch.2022.05.001_bb2060","unstructured":"Loose C, Tait B, Manchanda R, McLean W, Frequency Therapeutics, Inc., USA. Preparation of 1H-pyrrole-2,5-dione compounds as GSK3 inhibitors and methods of using them as inducers of stem\/progenitor supporting cells. WO2018125746A1. 2018."},{"key":"10.1016\/bs.pmch.2022.05.001_bb2065","unstructured":"McLean W, Loose C, Frequency Therapeutics, Inc., USA. Valproic acid compounds and Wnt agonists for treating ear disorders. WO2020163812A1. 2020."},{"key":"10.1016\/bs.pmch.2022.05.001_bb2070","unstructured":"McLean W, Manchanda R, Khedkar S, Strong RA, Jr., Banks A, Tait B, et al., Frequency Therapeutics, Inc., USA. Pharmaceutical compositions comprising otic therapeutic agents and related methods. WO2020072601A1. 2020."},{"key":"10.1016\/bs.pmch.2022.05.001_bb2075","unstructured":"Clayton JR, Diefenbacher CG, Engler TA, Furness KW, Henry JR, Malhotra S, et al., Eli Lilly and Company, USA; Preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted 2,5-dioxopyrroles as GSK-3\u03b2 kinase inhibitors. WO2003076442A1. 2003."},{"issue":"16","key":"10.1016\/bs.pmch.2022.05.001_bb2080","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1021\/jm049768a","article-title":"Substituted 3-Imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino- [6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase Kinase-3","volume":"47","author":"Engler","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2085","unstructured":"Piu F, Jacques B, Tsivkovskaia N, Qi H, Savel R, Coleman S, et al., Otonomy, Inc., USA. Growth factor otic formulations. WO2019140012A1. 2019."},{"key":"10.1016\/bs.pmch.2022.05.001_bb2090","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.neuropharm.2013.05.008","article-title":"The function of BDNF in the adult auditory system","volume":"76","author":"Singer","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2095","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2523458","article-title":"Mammalian Cochlear hair cell regeneration and ribbon synapse reformation","volume":"2016","author":"Lu","year":"2016","journal-title":"Neural Plast"},{"issue":"9","key":"10.1016\/bs.pmch.2022.05.001_bb2100","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrd.2016.164","article-title":"Trial watch: impact of genetically supported target selection on R&D productivity","volume":"15","author":"Hurle","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb2105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/378900","article-title":"\u201care we there yet?\u201d: deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits","volume":"73","author":"Page","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb2110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/hmg\/ddn402","article-title":"GRM7 variants confer susceptibility to age-related hearing impairment","volume":"18","author":"Friedman","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2022.05.001_bb2115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.heares.2012.08.016","article-title":"GRM7 variants associated with age-related hearing loss based on auditory perception","volume":"294","author":"Newman","year":"2012","journal-title":"Hear Res"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb2120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077153","article-title":"Association of GRM7 variants with different phenotype patterns of age-related hearing impairment in an elderly male Han Chinese population","volume":"8","author":"Luo","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb2125","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s12253-018-0388-6","article-title":"Age-related hearing impairment associated NAT2, GRM7, GRHL2 susceptibility gene polymorphisms and haplotypes in Roma and Hungarian populations","volume":"25","author":"Matyas","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.neuroscience.2014.05.057","article-title":"Metabotropic glutamate receptors in auditory processing","volume":"274","author":"Lu","year":"2014","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/bs.pmch.2022.05.001_bb2135","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100672R","article-title":"MGluR7 is a presynaptic metabotropic glutamate receptor at ribbon synapses of inner hair cells","volume":"35","author":"Klotz","year":"2021","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb2140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.112.200915","article-title":"ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization","volume":"344","author":"Kalinichev","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/bs.pmch.2022.05.001_bb2145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.107.124701","article-title":"In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists","volume":"323","author":"Suzuki","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2150","unstructured":"Duvey G, Celanire S, Pragma Therapeutics, Fr. Preparation of novel heterocyclic compounds 1-oxo-5,6,7,8-tetrahydro-2H-phthalazine derivatives and analogs, as mGluR7 modulators. WO2019063596A1. 2019."},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb2155","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1039\/D1CB00011J","article-title":"Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation","volume":"2","author":"Bond","year":"2021","journal-title":"RSC Chem Biol"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb2160","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100270","article-title":"Recent developments in PROTAC-mediated protein degradation: from bench to clinic","volume":"23","author":"Hu","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114142","article-title":"Emerging targeted protein degradation tools for innovative drug discovery: from classical PROTACs to the novel and beyond","volume":"231","author":"Zhong","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/bs.pmch.2022.05.001_bb2175","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2180","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2021.08.006","article-title":"The rise and rise of protein degradation: opportunities and challenges ahead","author":"Hughes","year":"2021","journal-title":"Drug Discov Today"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb2185","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov Today"},{"issue":"10","key":"10.1016\/bs.pmch.2022.05.001_bb2190","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1039\/C9MD00272C","article-title":"Developing degraders: principles and perspectives on design and chemical space","volume":"10","author":"Maple","year":"2019","journal-title":"Med Chem Commun"},{"issue":"13","key":"10.1016\/bs.pmch.2022.05.001_bb2195","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/bs.pmch.2022.05.001_bb2200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4155\/fmc-2021-0208","article-title":"PROTAC cell permeability and oral bioavailability: a journey into uncharted territory","volume":"14","author":"Poongavanam","year":"2022","journal-title":"Future Med Chem"},{"issue":"17","key":"10.1016\/bs.pmch.2022.05.001_bb2205","doi-asserted-by":"crossref","first-page":"7700","DOI":"10.1021\/acs.jmedchem.8b00669","article-title":"Development of second-generation CDK2 inhibitors for the prevention of cisplatin-induced hearing loss","volume":"61","author":"Hazlitt","year":"2018","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/bs.pmch.2022.05.001_bb2210","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1084\/jem.20172246","article-title":"CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss","volume":"215","author":"Teitz","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/bs.pmch.2022.05.001_bb2215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113849","article-title":"AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss","volume":"226","author":"Hati","year":"2021","journal-title":"Eur J Med Chem"}],"container-title":["Progress in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646822000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646822000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:29:52Z","timestamp":1762230592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079646822000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323989039"],"references-count":444,"URL":"https:\/\/doi.org\/10.1016\/bs.pmch.2022.05.001","relation":{},"ISSN":["0079-6468"],"issn-type":[{"type":"print","value":"0079-6468"}],"subject":[],"published":{"date-parts":[[2022]]}}}